54 results about "Humanin" patented technology

The invention discloses a fusion protein of a bispecific antibody targeting a T cell and Her2 in series connection with IL-15 and a receptor thereof and an application of the fusion protein. Belongs to the technical field of biology. The fusion protein disclosed by the invention can be combined with a recombinant human CD3 protein and a recombinant human Her2 protein, can be combined with NK92 and SK-BR-3 cell lines, can stimulate NK92 cell proliferation, and can respectively cause ADCC effects mediated by T and NK cells; the antibody has important economic and social significance.

A conditionally active bispecific antibody comprising: an IgG antibody or antibody fragment that binds to human EpCAM protein, the IgG antibody or antibody fragment comprising a light chain variable region having three complementarity-determining regions L1, L2, and L3, and a heavy chain variable region having three complementarity-determining regions H1, H2, and H3; and at least one scFv antibody fragment that binds to a T lymphocyte protein linked to the C-terminus of at least one light chain of the IgG antibody or antibody fragment.

Compositions and methods for the treatment of retinal degeneration are provided. In one aspect, provided herein is adeno-associated virus (AAV) vector comprising an AAV capsid having encapsidated therein a vector genome comprising AAV inverted terminal repeat (ITR) sequences, a human protein kinase B (AKT) coding sequence, and expression control sequences that direct expression of AKT in a host cell.

The present application provides a monoclonal antibody targeting human carcinoembryonic antigen CEACAM5 / 6, and a bispecific antibody capable of simultaneously targeting human carcinoembryonic antigen CEACAM5 / 6 and human CD47, a preparation method and applications. Specifically, it relates to an anti-human CD47 antibody and antigen-binding fragments thereof capable of simultaneously (1) specifically binding to human CD47 protein and blocking its binding to SIRPalpha, thereby thus blocking the inhibitory effect of CD47 on SIRPalpha-expressing macrophages; (2) specifically binding to human carcinoembryonic protein CEACAM5 / 6. The present application also relates to a preparation method and uses of the bispecific antibody.

The application relates to the technical field of biological medicine, and provides an anti-GPC3 full humanization single-domain antibody and application thereof. The application uses phage display technology to obtain one anti-human GPC3 specificity full humanization monoclonal single-domain antibody through antibody screening by targeting human GPC3 protein. The obtained single-domain antibody can be specifically combined with human GPC3, and can effectively inhibit the nuclear translocation of YAP, provides an effective alternative antibody drug for GPC3-targeted HCC treatment, and has a potential clinical application prospect.

The invention relates to the technical field of biological medicine, in particular to a specific antibody for detecting or targeting ALDOA-K13 succinylation modification and application of the specific antibody. The specific antibody for detecting or targeting ALDOA-K13 succinylation modification can be specifically combined with a succinylation modification site of 13th lysine of human ALDOA protein, and is not combined with ALDOA of an unmodified type or other modified types. The invention provides a specific antibody for detecting or targeting ALDOA-K13 succinylation modification for the first time, and fills the blank of existing detection tools. The antibody not only has high specificity and sensitivity, but also can be used for developing a novel tumor diagnosis and prognosis detection method.

Provided herein are bispecific and multispecific antibodies that target tumor antigens and 4-1BB, the Fc region of which has a retained or enhanced effector function; in particular, the multispecific antibodies have binding specificity for human ROR1 protein and human 4-1BB protein. Also provided herein are methods of treating cancer using the antibodies or fragments thereof.

The invention discloses a polypeptide targeting CD38, a ligand of the polypeptide, a coupling drug and application of the polypeptide, and the polypeptide targeting CD38 has an obvious binding signal with human CD38 protein, which shows that the polypeptide targeting CD38 has very high targeting property on CD38. A ligand or a coupling drug can be prepared from any sequence of the peptide targeting CD38, or a combination of a plurality of sequences, and an active drug is loaded or connected. The compound has a good killing result on cells such as MM.1 S, MOLP-8, HL-60, MV-4-11, Kasumi-1, K562 and KG-1, and has a relatively high growth inhibition rate on tumor cells such as a human multiple myeloma MOLP-8 cell strain and a human leukemia tumor cell HL-60 cell strain.

An in vitro method of detecting one or more endotoxins of one or more pathogens in a sample, comprising the steps of a. coating a lipid binding protein on a substrate or capturing a lipid binding protein on a capture molecule immobilized on a substrate, b. contacting the lipid binding protein, thus coated or captured, with the sample, c. detecting whether an endotoxin binds to the lipid binding protein, wherein the one or more endotoxins comprise a lipid A moiety and O- polysaccharide moiety, wherein the lipid binding protein is capable of binding the lipid A moiety of an endotoxin, and characterized in that the lipid binding protein is a mammalian protein and preferably is a murine or human protein.

Herein is reported an anti-TREM2 / A [beta] protein antibody comprising a first binding site that binds to human TREM2 and a second binding site that binds to human A [beta] protein, the first binding site comprising: a heavy chain variable domain comprising HVR-H1 of SEQ ID NO: 305, HVR-H2 of SEQ ID NO: 306 and HVR-H3 of SEQ ID NO: 307, and a light chain variable domain comprising HVR-L1 of SEQ ID NO: 309, HVR-L2 of SEQ ID NO: 310 and HVR-L3 of SEQ ID NO: 311 (TREM 23295), or a heavy chain variable domain comprising HVR-L1 of SEQ ID NO: 309, HVR-L2 of SEQ ID NO: 310 and HVR-L3 of SEQ ID NO: 311 (TREM 23295); the present invention relates to a single-chain variable domain comprising an HVR-H1 of SEQ ID NO: 329, an HVR-H2 of SEQ ID NO: 330, and an HVR-H3 of SEQ ID NO: 331, and a light chain variable domain comprising an HVR-L1 of SEQ ID NO: 333, an HVR-L2 of SEQ ID NO: 334, and an HVR-L3 of SEQ ID NO: 335 (TREM 23306); and a second binding site comprising: a heavy chain variable domain comprising HVR-H1 of SEQ ID NO: 09, HVR-H2 of SEQ ID NO: 10 and HVR-H3 of SEQ ID NO: 11, and in a light chain variable domain, HVR-L1 of SEQ ID NO: 13, HVR-L2 of SEQ ID NO: 14 and HVR-L3 of SEQ ID NO: 15 (A [beta] 8675).

Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25.

The present invention discloses a multifunctional recombinant antibody and its preparation method and application. The present invention not only provides a monoclonal antibody that can specifically recognize human HER3 protein, but also provides its humanized recombinant antibody, and further reconstructs on this basis to obtain a multifunctional antibody that can recognize human HER3 and has IL15 function, which can effectively enhance the killing effect of the original antibody on tumor cells. At the same time, the present invention also obtains a reconstructed specific HER3 monoclonal antibody-IL15 bifunctional molecule by introducing a mutated human IgG1 constant region, which can effectively reduce the toxicity of the antibody and improve safety. The antibody of the present invention can recognize HER3 protein in a variety of tumor cells, and then has a killing effect on a variety of tumor cells. At the same time, the reconstructed multifunctional recombinant antibody has the advantages of a short drug metabolism cycle, low toxicity and high safety, and has great application prospects.

The present disclosure provides antibodies or fragments thereof having binding specificity for human ROR1 protein. In various examples, the antibodies or fragments thereof comprise VH CDRs and VL CDRs, or variants thereof, as disclosed herein. The disclosure also provides methods of treating cancer using the antibodies or fragments thereof.

The application belongs to the technical field of biotechnology, and particularly relates to an anti-TL1A nanobody and application thereof. The amino acid sequences of the complementarity determining regions CDR1, CDR2 and CDR3 of the nanobody are respectively shown as SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO:1. The application uses a llama natural nanobody library and combines phage display technology to successfully screen a high-affinity nanobody targeting TL1A. The antibody can specifically recognize human TL1A protein and a TL1A overexpression cell line, and has high affinity, high specificity and good physicochemical stability. Based on the characteristic of targeting TL1A, the nanobody has important application value in the precise diagnosis and targeted treatment of TL1A high-expression related diseases such as inflammatory bowel disease, rheumatoid arthritis, asthma and fibrosis, and is particularly suitable for developing a high-sensitivity in-vitro diagnostic kit and a novel biological therapeutic drug.

The invention belongs to the technical field of biology, and relates to a fully human anti-BCMA monoclonal antibody, a tandem antibody and application thereof. The invention provides an elutriation method of a BCMA protein monoclonal antibody, preparation of an IgG antibody and optimization of a series antibody of the IgG antibody. The scFv monoclonal antibody is composed of a light chain variable region VL, a heavy chain variable region VH and a human Fc fragment. The base sequence of the scFv monoclonal antibody is as shown in SEQ ID No.9, and the amino acid sequence of the scFv monoclonal antibody is as shown in SEQ ID No.23. The anti-human BCMA IgG antibody can specifically recognize and bind to human BCMA protein, and the binding activity of the anti-human BCMA IgG antibody is remarkably improved after the anti-human BCMA IgG antibody is expressed in a series scFv antibody form. The tandem antibody has a wide application prospect in detection of human BCMA protein and treatment of related target diseases, and a new idea is provided for development of antibody diagnostic reagents and drugs.

The application discloses application of recombinant human USP13 protein in preparation of a drug for treating diabetic cardiomyopathy, and belongs to the technical field of biological medicines.The application first proves that the expression of USP13 in myocardial tissue and serum is significantly reduced under the condition of diabetic cardiomyopathy (DCM); the recombinant human USP13 protein can obviously reduce the level of myocardial cell active oxygen, reduce the expression of NLRP3 inflammasome and active Caspase3 protein in a DCM in-vitro model induced by high sugar / palmitic acid; in a DCM mouse model injected with the recombinant human USP13 protein through a tail vein, myocardial cell apoptosis is inhibited, and the expression of NLRP3 inflammasome and the synthesis of TNF-alpha in the heart of the animal are reduced.USP13 is a human protein, has no obvious toxic side effects, is high in safety, is small in immunological rejection in theory, provides a new effective drug for the clinical treatment of DCM, and has important clinical application value and industrialization prospect.

Disclosed in the present invention are an EGFR x HER3 bispecific antibody-drug conjugate, a preparation method therefor, and use thereof. The structure of the antibody-drug conjugate is A-(L1-L2-L3-T)n, wherein A refers to an antibody; L1 refers to a coupling linker; L2 refers to x PEG spacers; L3 refers to an enzymatically cleavable or cleavable linker, or a non-cleavable linker; and T refers to an active small molecule. The antibody-drug conjugate provided in the present invention can bind to an HER3 protein of a human EGFR protein, has cytotoxicity to cancer cells expressing EGFR and / or HER3, and exhibits better efficacy and safety in in vivo tumor treatment.

The present disclosure provides an antibody or an antigen-binding fragment thereof, which specifically binds to PVRIG, has high binding affinity to human PVRIG protein and cynomolgus PVRIG protein, and has strong activity in both reporter gene level and CD8 T cell activation. Compared with known SRF813 and COM701, the antibodies of the present application exhibit more optimal in vitro activity, and some of the antibodies combined with PD-1 antibodies have obvious anti-tumor effect, making them excellent candidate drug molecules for therapeutic and diagnostic use.

The present disclosure provides a modified human OTC protein having improved properties for the treatment of OTC deficiency in a patient. Preferably, the protein of the disclosure is produced from a codon optimized mRNA suitable for administration to a patient suffering from OTC deficiency wherein upon administration of the mRNA to the patient, the protein of the disclosure is expressed in the patient in therapeutically effective amounts to treat OTC deficiency. The present disclosure also provides codon optimized mRNA sequences encoding wild type human OTC comprising a 5′ UTR derived from a gene expressed by Arabidopsis thaliana for use in treating OTC deficiency in a patient.

The present application relates to the field of physiology and molecular biology, and discloses an m 6 The present application relates to the field of physiology and molecular biology, and discloses an m 6 A binding protein IGF2BP3 ubiquitination and its application in preparation of an anti-tumor drug targeting RNA binding protein. Protein spectrum technology is used to screen the ubiquitination site of IGF2BP3, and the site mutation verifies that the ubiquitination site of IGF2BP3 is K213, which is located in the first KH domain of IGF2BP3. The functional analysis results show that after the mutation of IGF2BP3, the binding of IGF2BP3 with downstream tumor-related genes is weakened, the expression of the downstream tumor-related genes is down-regulated, and the growth of cervical cancer cells is inhibited, which indicates that ubiquitination modification is an important regulation mode affecting the function of IGF2BP3.

Herein is reported an antibody that binds to human A-beta protein wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain, the heavy chain variable domain and the light chain variable domain comprising a CDR selected from the group consisting of: (1) a CDR of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) a CDR of SEQ ID NO: 85, 89, 87, 81, 82, and 83; or (3) a CDR of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

The disclosure provides agents and methods for preventing or treating diseases associated with one or more antigens. The agents of the invention comprise RNA encoding chimeric proteins comprising an antigenic region. The antigenic region comprises one or more disease-associated antigens, immunogenic variants of fragments thereof. According to the invention, the chimeric proteins, in addition to the antigenic region, comprise a transmembrane domain and cytoplasmatic region, one or both of which are derived from a MHC-I homolog non-native to an organism from which the antigen originates.

Provided herein are antibodies or fragments thereof having binding specificity for human CD24 protein. In various examples, the antibodies or fragments thereof include VH and VL CDRs, or variants thereof, as disclosed herein. Also provided herein are methods of using the antibodies or fragments thereof to treat cancer.

The invention belongs to the technical field of gene therapy, and particularly relates to a recombinant expression system for expressing human GLB1 protein, a protein expression cassette, a recombinant adeno-associated virus vector and application of the recombinant adeno-associated virus vector in prevention and treatment of GM1 ganglioside storage diseases. In order to solve the problem that in an existing GLB1 gene expression system, due to the fact that a transcriptional regulation element combination is not systematically optimized, the expression efficiency in a central nervous system is insufficient, the codon-optimized human GLB1 gene and various different promoter-intron combinations are subjected to systematic pairing and functional verification; it is found that a recombinant expression system formed by a CB7 promoter-chimeric intron 1-codon optimized human GLB1 gene (SEQ ID NO: 2) is packaged into a recombinant adeno-associated virus AAV9.CB7. HGLB1co.bGH, the effect of treating the GM1 ganglioside storage disease is most remarkable, and the GM1 ganglioside storage disease is expected to be efficiently and safely prevented and radically treated.

The present application relates to the technical field of biotechnology, in particular to anti-human MxA antibody or functional fragment thereof and application thereof. The present application provides a plurality of monoclonal antibodies with high affinity to human MxA protein through computer simulation technology, and verifies the affinity of each mutation and its related application, thereby providing a reference for the research in the field of immune detection of human MxA.

The invention belongs to the technical field of biological medicines, and particularly discloses a polypeptide for protecting lung vascular endothelial cells and relieving lung injury and application of the polypeptide. The polypeptide is Humanin-G (HNG), and the amino acid sequence of the polypeptide is MAPRGFSCLLLLTGEIDLPVKRRA. The polypeptide is targeted to mitochondria of pulmonary vascular endothelial cells, provides protection from energy supply and cell survival roots, and has profound significance in improving functions of the pulmonary vascular endothelial cells and reducing the death rate of sepsis-induced acute lung injury (ALI). Researches show that when the polypeptide is used in the acute injury stage, lung inflammation of a model animal can be relieved by 25%-50%, the lung injury HE score can be reduced by about 50%, pulmonary edema can be relieved by about 30%, mitochondrial functions can be recovered by about 70%, the ATP yield can be increased by 30%, and the effect is excellent. Therefore, the invention provides a brand new strategy for maintaining the mitochondrial homeostasis by using the polypeptide so as to relieve lung injury.

The present invention relates to a construct comprising a cell penetrating peptide sequence coupled by a peptide bond to at least one first binding molecule which is coupled by a peptide bond to the N-terminal end of an interfering amino acid sequence chosen from the following sequences: SEQ ID NO: 1 which forms domain 2104-2206 of the human FlnA protein and SEQ ID NO: 2 which defines domain 330-350 of the UT receptor, the sequences having at least 90% identity and, preferably, at least 95% identity with the abovementioned sequences and the sequences substantially homologous to the abovementioned sequences and preferably deriving from the latter by one or more conservative substitutions.

The invention discloses an anti-CD209 antibody, a product, a nucleic acid molecule, a carrier, a cell and application thereof, and relates to the technical field of biomedicine. The invention provides a new therapeutic scheme for accelerating deterioration of tumors by inhibiting T cells through the ligand CD209, the anti-human CD209 monoclonal antibody can specifically recognize CD209 and bind with CD209, so that the human cell surface ligand CD209 is closed, the CD209 cannot inhibit the functions of the T cells, the anti-tumor immunity is enhanced, the tumor growth is obviously inhibited, the lifetime is prolonged, and the anti-human CD209 monoclonal antibody can be used for treating the tumors. The active anti-tumor function is realized in various solid tumors. In addition, the monoclonal antibody provided by the invention can be used for detection, separation and enrichment of human CD209 protein.

The application relates to the technical field of biological detection, in particular to an anti-p16 protein antibody and a preparation method and application thereof. The anti-p16 protein antibody has CDRs shown in SEQ ID NO. 2-SEQ ID NO. 7 or has CDRs shown in SEQ ID NO. 8-SEQ ID NO. 13. The application provides a new anti-p16 protein antibody which can be used for development of an in vitro diagnosis kit and applied to quantitative detection of human p16 protein in a clinical sample.

This invention belongs to the field of biomedical technology and relates to a monoclonal antibody targeting BTN3A1 and its uses. The monoclonal antibody B1B7G2E4 of this invention has high human BTN3A1 binding activity and binding affinity, specifically binding to the human BTN3A1 protein on the cell membrane surface. It also cross-reacts with cynomolgus monkey BTN3A1, has a novel sequence, and is a new anti-BTN3A1 monoclonal antibody. Monoclonal antibodies targeting BTN3A1 have broad application prospects and can be used to treat various types of tumors. Furthermore, this antibody can be used in combination with other immunotherapies to improve overall treatment efficacy.